You have read all your free articles, to continue reading subscribe to read the rest of this content.
Lipigon Pharmaceuticals has signed a new agreement with Chinese biotech company HitGen to develop drug candidates that treat blood fat disorders and cardiovascular diseases. Lipigon, which is located at the Umeå Biotech Incubator, specializes in developing medicines for lipid-related disorders, Already a subscriber Login You have read all your free…
ObsERV identifies patient-specific virus targets, so-called ERVs (endogenous retroviruses), expressed in cancer. Evaxion has demonstrated that overexpression of such ERVs is strongly associated with the overall survival of cancer patients, notably of patients that are normally considered unresponAlready a subscriber Login You have read all your free articles, to continue…
BioInvent International has announced the presentation of promising new data on its anti-tumor necrosis factor receptor 2 (TNFR2) program at the American Association for Cancer Research (AACR) Annual Meeting. The results shows that TNFR2 is particularly upregulated on tumor-associated regulatory Already a subscriber Login You have read all your free…
CytoSorbents Corporation announced that it has entered into a multi-country strategic partnership with Fresenius Medical Care AG & CO KGaA to commercialize CytoSorbents' CytoSorb® therapy in the Nordic countries. Under the terms of the agreement, Fresenius Medical Care will have the excAlready a subscriber Login You have read all…
